Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records. -
Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer. -
ACE2 Pathway Stimulation Enhances VEGF Inhibition in ccRCC, May Help Overcome VEGF Resistance
New study data offer insight on the mechanisms of angiotensin converting enzyme 2 (ACE2) in clear cell renal cell carcinoma (ccRCC). -
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends
The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
UROLOGIC CANCERS NEWS
Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma
Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC
Combo Continues to Show Superior Efficacy vs Sunitinib in Advanced Clear Cell Renal Cell Carcinoma
Pembrolizumab After RCC Surgery: Potential New Standard of Care
Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
Loading... 
Loading...